Skyline Medical Inc. — Form 10-Q Summary
Important identity discrepancy: The request identifies Axe Compute Inc., but the supplied filing is for Skyline Medical Inc. This summary reflects the filing provided and should not be attributed to Axe Compute without verification.
Business context and reporting period
The filing covers the quarter and nine months ended September 30, 2014. Skyline develops and sells the STREAMWAY system, which collects and disposes of surgical fluids, as well as related cleaning fluid and filter kits. The company reported selling 70 systems cumulatively through September 30, 2014; nine-month 2014 revenue included 43 system sales. Figures and per-share amounts were retrospectively adjusted for a 1-for-75 reverse stock split effective October 24, 2014.
Key financial metrics
| Metric | Q3 2014 | Q3 2013 | Nine months 2014 | Nine months 2013 |
|---|---|---|---|---|
| Revenue | $397,254 | $107,835 | $785,767 | $386,418 |
| Gross profit | $262,528 | $81,654 | $521,593 | $251,298 |
| Gross margin | 66.1% | 75.7% | 66.4% | 65.0% |
| Net loss available to common shareholders | $(1,115,221) | $(3,974,903) | $(4,468,170) | $(7,251,965) |
| Loss per share, basic and diluted | $(0.37) | $(2.18) | $(1.51) | $(4.30) |
- Cash flow, nine months: Operating cash use was $3.143 million; investing cash use was $122,300; financing provided $3.407 million. Cash increased $142,091 to $244,044.
- Liquidity at September 30: Current assets were $947,218 and current liabilities $4.842 million, implying a working-capital deficit of approximately $3.895 million. Total liabilities were $5.072 million; stockholders’ deficit was $3.835 million.
- Debt and financing: The balance sheet reported short-term notes payable, net of discounts, of $1.170 million. Management separately cited approximately $5.208 million of debts, liabilities and cash obligations predominantly due within 12 months. The company raised $2.055 million gross in a February preferred-stock placement and $1.475 million net from 2014 convertible-note financing.
Material changes versus prior period
- Nine-month revenue more than doubled year over year, while the net loss narrowed by approximately $2.784 million. Q3 revenue also rose substantially, and the quarterly net loss narrowed by approximately $2.860 million.
- The lower reported losses reflected much lower general and administrative expense, principally because stock-based and investor compensation expense was lower. For the nine-month period, G&A fell $2.660 million; sales and marketing expense rose $492,000, reflecting increased sales staffing and related costs.
- Interest expense fell $465,000 for the nine months, which management attributed principally to the elimination of earlier convertible notes, partly offset by original-issue discounts on new bridge financing.
- Cash used in operations remained significant. Financing included preferred stock and convertible notes, while accounts payable and accrued expenses also increased.
Outlook, risks and unusual items
- Going concern and funding: The filing says recurring losses and the stockholders’ deficit raise substantial doubt about the company’s ability to continue as a going concern. Management estimated available cash would last approximately through November 30, 2014, after which additional financing would be needed. It expected ongoing losses and higher operating, sales and marketing, and administrative expenses.
- Management expectations: Management expected revenue to increase as hospitals convert trials into purchases, and anticipated improved margins with more consistent production and volume purchasing. These expectations were subject to market acceptance, product and other risks; no quantified formal financial guidance was provided.
- Convertible-note terms and dilution: The 2014 notes bear 12% interest, mature in July 2015, and have conversion prices linked to recent trading prices, subject to a 72.5% multiplier (70% after a continuing default) and an $11.25 cap, adjusted for stock splits. The notes also have default and redemption provisions. The preferred-stock conversion price was adjusted to $9.75 in July 2014.
- Settlement: A July 2014 settlement resolved litigation with a former product engineer. Skyline agreed to pay $500,000 through April 25, 2015, including $200,000 due during the remainder of 2014. Certain fundraising levels can accelerate payment. The settlement confirms Skyline’s rights to the relevant patent assignments and STREAMWAY intellectual property.
- Commercial and operational risks: The company remained dependent on raising capital and converting hospital trials into paid system orders. Management cited delayed cash collections, limited operating history, and risks including lower-than-expected sales, adverse legal outcomes, and difficulty attracting or retaining qualified personnel.
- Capital structure: The company issued additional warrants to preferred holders after failing to meet a specified exchange-listing condition within 180 days. It also filed a public-offering registration statement and applied to list on Nasdaq, contingent on completion of the offering.
Most important facts for investors to verify
- Confirm the issuer: the provided document is Skyline Medical Inc., not Axe Compute Inc.
- Verify the company’s financing since the stated November 30, 2014 cash runway, and its ability to meet near-term obligations and settlement payments.
- Review the full terms, conversion mechanics, default remedies, and potential dilution from convertible notes, preferred shares, warrants, and the contemplated public offering.
- Assess whether hospital trials convert into recurring system and consumables revenue, and whether sales volumes support the company’s margin expectations.
- Reconcile share and loss-per-share disclosures: the statements report Q3 weighted-average shares of 2,984,335, while a loss-per-share note contains inconsistent denominator figures.